index - Myopathies inflammatoires & thérapies innovantes ciblées Accéder directement au contenu

Dernières publications

Chiffres clés

121 Publications avec texte intégral

Open Access

53 %

Mots clés

Biopsy Cytokines Acute Kidney Injury/epidemiology/etiology Amyotrophic lateral sclerosis Antisynthetase Auto-immunité Data integration Arthritis Outcome measures AAV vector Anti-drug antibodies Gene therapy Anti-interleukin-6 Case reports Inborn errors of metabolism Anti-synthetase syndrome Auto‐antibodies Anticorps spécifique des myosites Antibody responses Active DM Anti-Mi2 Machine learning Muscle Anémie hémolytique Mass cytometry Autoantibody Idiopathic inflammatory myopathies Polymyositis Auto-antibodies Dependovirus/genetics/immunology AAV antibody Abnormal movement Biomarkers Fabry disease IBM Myocarditis Antiphospholipid syndrome Aldosterone AAV Antibodies Myopathy Autoimmune diseases Immunotherapy Myositis and muscle disease Systems biology CD8+T cells Biomarker Adeno-associated vector Female Anti‐mitochondrial antibodies CD8+ T-bet+ cells Antisynthetase syndrome Adeno-associated virus Cancer Sphingosine-1-phosphate Adolescence Adjudication Lysosomal storage diseases Dermatomyositis Multidisciplinarity Inflammation Middle Aged Biomarqueurs AAV humoral immunity Inflammatory myopathy Humans Anti-IgE IgG Myositis Autoimmunity AAV vectors Anti-MDA5 autoantibodies Adeno-associated virus vector B cell homeostasis Male Adverse drug reactions Acid-alpha-glucosidase Assisted communication devices Agalsidase Aged Antisynthétase Analyses multidimensionnelles Amyotrophy Interstitial lung disease COVID-19 Anticorps anti-agalsidase Immune checkpoint inhibitors Bioelectrical impedance analysis B-lymphocyte Prognosis Aldostérone Animals Inclusion body myositis Skeletal muscle Adult Deep immune profiling IMNM Interferon Autoantibodies Anti-agalsidase antibodies